ZLAB / Most Chinese Biotech Stocks Can Continue US Listing After New Audit Framework

Zai Lab Limited is a biotech company that acts as a powerful partner for other biotechs to launch drug candidates in China. They currently distribute more_horizontal

SHANGHAI, China and CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the more_horizontal

Zai Lab Limited's recent clinical study results and partnerships demonstrate its commitment to innovation and product development, positioning it as a more_horizontal

Zai Lab collaborated with NovoCure on a study to treat non-small cell lung cancer. There were some concerns about the validity of the study. more_horizontal

Many Wall Street analysts still see an economic recovery playing out in China. President Biden recently said he expects relations with China to improv more_horizontal

Zai Lab will soon launch a handful of new medicines in China. It's also seeking approval for many of its therapies in the U.S. The company also has en more_horizontal

Biotech stocks are risky, but high-potential plays can pay off big. Compass Pathways is making progress towards commercializing its first therapy. more_horizontal

Over the next 10 to 20 years, some of healthcare's most impactful innovations will come from biotechnology companies. They'll produce medicines based more_horizontal